Tobacco industry ownership of pharmaceutical companies: an international survey of people with respiratory disease.
Thorax
; 77(10): 1045-1047, 2022 10.
Article
em En
| MEDLINE
| ID: mdl-35970539
ABSTRACT
The 2021 purchase of the respiratory pharmaceutical company Vectura by Phillip Morris International has been criticised by the public health and medical community, as a conflict of interest, with little input to date, from the patient community or the public. To address this gap, the COPD Foundation, along with global partners, surveyed 1196 people with chronic respiratory disease. 70% were bothered by a tobacco company making an inhaler to treat lung conditions and 48% reported that they would want to switch inhalers if they knew that a tobacco company made or sold their inhaler devices. Patients care about who makes the therapies used to treat their diseases.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transtornos Respiratórios
/
Doenças Respiratórias
/
Indústria do Tabaco
/
Doença Pulmonar Obstrutiva Crônica
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article